Katherine Clifton, MD - Medical Student ...

Dr. Katherine Clifton, MD

Claim this profile

Washington University School of Medicine

Studies Breast Cancer
Studies Breast cancer
12 reported clinical trials
29 drugs studied

Area of expertise

1Breast Cancer
Katherine Clifton, MD has run 10 trials for Breast Cancer. Some of their research focus areas include:
HER2 negative
Stage IV
Stage II
2Breast Cancer
Katherine Clifton, MD has run 4 trials for Breast cancer. Some of their research focus areas include:
Stage IV
HER2 negative
Stage III

Affiliated Hospitals

Image of trial facility.
Washington University School Of Medicine
Image of trial facility.
Washington University

Clinical Trials Katherine Clifton, MD is currently running

Image of trial facility.

Cryoablation

for Breast Cancer

This is a subject registry study of patients who undergo cryoablation for their breast cancer after being determined not to be surgical candidates. Data collected as part of this registry will be used to assess the safety of percutaneous ultrasound-guided cryoablation in this population as well as provide long-term follow-up of subjects who received cryoablation.
Recruiting1 award N/A8 criteria
Image of trial facility.

Biomarker-Driven Therapy

for Breast Cancer

This is a prospective study to assess the impact of biomarker driven, early therapeutic switching and delayed imaging with the incorporation of DiviTum® serum TK1 activity ("DiviTum® TKa") in patients with HR positive, HER-2 negative metastatic or unresectable breast cancer. Patients will receive first-line treatment with a CDK4/6 inhibitor (CDK4/6i) and endocrine therapy. All patients will have blood drawn for thymidine kinase activity (TKa) testing at baseline and at C1D15. Patients who are found to have a lack of TKa suppression at C1D15 will be recommended to switch to an alternative therapy. Patients with suppressed C1D15 TKa levels will continue on CDK4/6i and endocrine therapy until clinical progression. Patients with TKa which remains suppressed will be recommended to delay restaging scans from 24 weeks to 36 weeks. The investigators hypothesize that a patient's TKa level at C1D15 is prognostic for progression-free survival (PFS) on a CDK4/6 inhibitor and early therapeutic switching in patients with a lack of C1D15 TKa suppression will be associated with prolonged PFS.
Recruiting1 award N/A9 criteria

More about Katherine Clifton, MD

Clinical Trial Related2 years of experience running clinical trials · Led 12 trials as a Principal Investigator · 6 Active Clinical Trials
Treatments Katherine Clifton, MD has experience with
  • DiviTum® TKa Assay
  • Paclitaxel
  • CDK4/6 + Endocrine Therapy
  • Nivolumab
  • Blood Draw
  • Tumor Biopsy

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Katherine Clifton, MD specialize in?
Is Katherine Clifton, MD currently recruiting for clinical trials?
Are there any treatments that Katherine Clifton, MD has studied deeply?
What is the best way to schedule an appointment with Katherine Clifton, MD?
What is the office address of Katherine Clifton, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security